These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 21707530)
1. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature. Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Motzer RJ; Hoosen S; Bello CL; Christensen JG Expert Opin Investig Drugs; 2006 May; 15(5):553-61. PubMed ID: 16634693 [TBL] [Abstract][Full Text] [Related]
3. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis. Pasqualetti G; Ricci S; Boni G; Tognini S; Polini A; Mariani G; Ferdeghini M; Monzani F Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):171-6. PubMed ID: 22533521 [TBL] [Abstract][Full Text] [Related]
5. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Hiles JJ; Kolesar JM Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256 [TBL] [Abstract][Full Text] [Related]
6. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455 [TBL] [Abstract][Full Text] [Related]
7. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature. Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554 [TBL] [Abstract][Full Text] [Related]
8. Sunitinib for the treatment of thyroid cancer. Gómez-Sáez JM Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828 [TBL] [Abstract][Full Text] [Related]
9. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268 [TBL] [Abstract][Full Text] [Related]
17. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632 [TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827 [TBL] [Abstract][Full Text] [Related]
19. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562 [TBL] [Abstract][Full Text] [Related]
20. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients. Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]